Rostock K J, Rathgen K, Pfeiffer D, Rostock G
Pharmazie. 1985 Dec;40(12):862-4.
The effects of the new antiarrhythmic drug 3-carbethoxy-amino-5-dimethyl-amino-acetyl-iminodibenzyl-hydroc hlorid (Bonnecor) (B.) were investigated by means of clinical-electrophysiologic methods (His-bundle electrography, programmed electrical stimulation) in 11 patients with normal cardiac output and paroxysmal supraventricular tachycardias. In a maximal dosage of 0.24 mg/kg body mass. B. affects several compartments of the impulse initiation and conduction. B. has positive chronotropic actions on the sinus node automaticity, negative dromotropic effects on the sinu-atrial, intraatrial, AV nodal and intraventricular conduction and finally negative bathmotropic actions on the myocardium of the atria and ventricles. B. suppress the artificial induction of paroxysmal supraventricular tachycardias in patients with AV nodal reentry. These results help to recognize indications (supraventricular and ventricular premature beats or tachycardias) and contraindications (sick sinus syndrome, atrio-ventricular block of higher degreé and bifascicular blocks).
采用临床电生理方法（希氏束电图、程控电刺激）对11例心输出量正常且患有阵发性室上性心动过速的患者，研究了新型抗心律失常药物3 - 乙氧羰基氨基 - 5 - 二甲氨基 - 乙酰亚氨基二苄基盐酸盐（邦尼可）（B.）的作用。在最大剂量为0.24mg/kg体重时，B.影响冲动起始和传导的多个环节。B.对窦房结自律性有正性变时作用，对窦房结、心房内、房室结和心室内传导有负性变传导作用，最终对心房和心室肌有负性变力作用。B.可抑制房室结折返患者阵发性室上性心动过速的人工诱发。这些结果有助于明确适应证（室上性和室性早搏或心动过速）和禁忌证（病态窦房结综合征、高度房室传导阻滞和双分支阻滞）。
